A systematic review and meta-analysis of the risk of diarrhea associated with vandetanib treatment in carcinoma patients.

ABSTRACT:

Background and purpose

Vandetanib is a promising anticancer targeted agent for treating advanced carcinomas, such as non-small-cell lung cancer, small-cell lung cancer, breast cancer, malignant glioma, hepatocellular cancer, and unresectable, locally advanced, or metastatic medullary thyroid cancer. However, diarrhea is a frequently reported adverse event. The incidence of vandetanib-associated diarrhea varies extensively in different study populations and has not been carefully estimated. This systematic review and meta-analysis of clinical trials aims to figure out the overall risks of all-grade and high-grade diarrhea during vandetanib treatment and get a better understanding of its prediction and management.

Materials and methods

A comprehensive search was performed in E

SUBMITTER: Huo Z 

PROVIDER: S-EPMC4920236 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature